Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 32

1.

Antimalarial activity of hydromethanolic extract and its solvent fractions of Vernonia amygdalina leaves in mice infected with Plasmodium berghei.

Bihonegn T, Giday M, Yimer G, Animut A, Sisay M.

SAGE Open Med. 2019 May 13;7:2050312119849766. doi: 10.1177/2050312119849766. eCollection 2019.

2.

CYP2J27 Genotype Predicts Risk of Chemotherapy-Induced Hematologic Toxicity and Reduced Relative Dose Intensity in Ethiopian Breast Cancer Patients.

Ahmed JH, Makonnen E, Yimer G, Seifu D, Bekele A, Assefa M, Aseffa A, Howe R, Fotoohi A, Hassan M, Aklillu E.

Front Pharmacol. 2019 May 14;10:481. doi: 10.3389/fphar.2019.00481. eCollection 2019.

3.

Nephrotoxicity and ototoxic symptoms of injectable second-line anti-tubercular drugs among patients treated for MDR-TB in Ethiopia: a retrospective cohort study.

Shibeshi W, Sheth AN, Admasu A, Berha AB, Negash Z, Yimer G.

BMC Pharmacol Toxicol. 2019 May 23;20(1):31. doi: 10.1186/s40360-019-0313-y.

4.

Vitamin D Status and Association of VDR Genetic Polymorphism to Risk of Breast Cancer in Ethiopia.

Ahmed JH, Makonnen E, Fotoohi A, Yimer G, Seifu D, Assefa M, Tigeneh W, Aseffa A, Howe R, Aklillu E.

Nutrients. 2019 Jan 29;11(2). pii: E289. doi: 10.3390/nu11020289.

5.

Establishment of a Sentinel Laboratory-Based Antimicrobial Resistance Surveillance Network in Ethiopia.

Hazim C, Abubeker Ibrahim R, Westercamp M, Belete GA, Amare Kibret B, Kanter T, Yimer G, Adem TS, Stevenson KB, Urrego M, Kale KN, Omondi MW, VanderEnde D, Park BJ, Parsons MMB, Gallagher KM.

Health Secur. 2018 Fall;16(S1):S30-S36. doi: 10.1089/hs.2018.0052.

6.

Short-term impact of celebrating the international clinical trial day: experience from Ethiopia.

Fekadu A, Hailu A, Makonnen E, Belete A, Yimer G.

Trials. 2017 Jul 17;18(1):332. doi: 10.1186/s13063-017-2081-6.

7.

Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients.

Habtewold A, Aklillu E, Makonnen E, Yimer G, Bertilsson L, Burhenne J, Owen JS.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00207-17. doi: 10.1128/AAC.00207-17. Print 2017 Aug.

8.

Genome-Wide Association and Replication Study of Hepatotoxicity Induced by Antiretrovirals Alone or with Concomitant Anti-Tuberculosis Drugs.

Petros Z, Lee MT, Takahashi A, Zhang Y, Yimer G, Habtewold A, Schuppe-Koistinen I, Mushiroda T, Makonnen E, Kubo M, Aklillu E.

OMICS. 2017 Apr;21(4):207-216. doi: 10.1089/omi.2017.0019.

9.

HLA-B*57 Allele Is Associated with Concomitant Anti-tuberculosis and Antiretroviral Drugs Induced Liver Toxicity in Ethiopians.

Petros Z, Kishikawa J, Makonnen E, Yimer G, Habtewold A, Aklillu E.

Front Pharmacol. 2017 Feb 27;8:90. doi: 10.3389/fphar.2017.00090. eCollection 2017.

10.

Molecular typing of Mycobacterium tuberculosis complex isolated from pulmonary tuberculosis patients in central Ethiopia.

Bedewi Z, Worku A, Mekonnen Y, Yimer G, Medhin G, Mamo G, Pieper R, Ameni G.

BMC Infect Dis. 2017 Mar 1;17(1):184. doi: 10.1186/s12879-017-2267-2.

11.

Genome-wide association and replication study of anti-tuberculosis drugs-induced liver toxicity.

Petros Z, Lee MM, Takahashi A, Zhang Y, Yimer G, Habtewold A, Amogne W, Aderaye G, Schuppe-Koistinen I, Mushiroda T, Makonnen E, Kubo M, Aklillu E.

BMC Genomics. 2016 Sep 26;17(1):755.

12.

SLCO1B1 Gene Variations Among Tanzanians, Ethiopians, and Europeans: Relevance for African and Worldwide Precision Medicine.

Aklillu E, Habtewold A, Ngaimisi E, Yimer G, Mugusi S, Amogne W, Reuter T, Meid A, Hoffmann MM, Weiss J.

OMICS. 2016 Sep;20(9):538-45. doi: 10.1089/omi.2016.0119.

PMID:
27631193
13.

Prevalence and risk factors for efavirenz-based antiretroviral treatment-associated severe vitamin D deficiency: A prospective cohort study.

Nylén H, Habtewold A, Makonnen E, Yimer G, Bertilsson L, Burhenne J, Diczfalusy U, Aklillu E.

Medicine (Baltimore). 2016 Aug;95(34):e4631. doi: 10.1097/MD.0000000000004631.

14.

Efficacy and Safety of 'Fixed Dose' versus 'Loose' Drug Regimens for Treatment of Pulmonary Tuberculosis in Two High TB-Burden African Countries: A Randomized Controlled Trial.

Aseffa A, Chukwu JN, Vahedi M, Aguwa EN, Bedru A, Mebrahtu T, Ezechi OC, Yimer G, Yamuah LK, Medhin G, Connolly C, Rida W, Aderaye G, Zumla AI, Onyebujoh PC; 4FDC Study Group.

PLoS One. 2016 Jun 20;11(6):e0157434. doi: 10.1371/journal.pone.0157434. eCollection 2016.

15.

Elevated levels of circulating CDH5 and FABP1 in association with human drug-induced liver injury.

Mikus M, Drobin K, Gry M, Bachmann J, Lindberg J, Yimer G, Aklillu E, Makonnen E, Aderaye G, Roach J, Fier I, Kampf C, Göpfert J, Perazzo H, Poynard T, Stephens C, Andrade RJ, Lucena MI, Arber N, Uhlén M, Watkins PB, Schwenk JM, Nilsson P, Schuppe-Koistinen I.

Liver Int. 2017 Jan;37(1):132-140. doi: 10.1111/liv.13174. Epub 2016 Jun 22.

16.

Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients.

Habtewold A, Aklillu E, Makonnen E, Amogne W, Yimer G, Aderaye G, Bertilsson L, Owen JS, Burhenne J.

J Clin Pharmacol. 2016 Dec;56(12):1538-1549. doi: 10.1002/jcph.756. Epub 2016 May 29.

PMID:
27125860
17.

Effect of Rumex Abyssinicus on preneoplastic lesions in dimethylhydrazine induced colon carcinogenesis in rats.

Girma B, Yimer G, Makonnen E.

BMC Complement Altern Med. 2015 Oct 15;15:365. doi: 10.1186/s12906-015-0883-1.

18.

Ethics in global health research: the need for balance.

Ng LC, Hanlon C, Yimer G, Henderson DC, Fekadu A.

Lancet Glob Health. 2015 Sep;3(9):e516-7. doi: 10.1016/S2214-109X(15)00095-9. No abstract available.

19.

Efficacy and Safety of Antiretroviral Therapy Initiated One Week after Tuberculosis Therapy in Patients with CD4 Counts < 200 Cells/μL: TB-HAART Study, a Randomized Clinical Trial.

Amogne W, Aderaye G, Habtewold A, Yimer G, Makonnen E, Worku A, Sonnerborg A, Aklillu E, Lindquist L.

PLoS One. 2015 May 12;10(5):e0122587. doi: 10.1371/journal.pone.0122587. eCollection 2015.

20.

Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study.

Habtewold A, Makonnen E, Amogne W, Yimer G, Aderaye G, Bertilsson L, Burhenne J, Aklillu E.

Pharmacogenomics. 2015;16(10):1047-64. doi: 10.2217/pgs.15.35. Epub 2015 Apr 1.

Supplemental Content

Loading ...
Support Center